Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zynex, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements, leading to inflated revenue and potential penalties from insurers and the federal government [1][2]. Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, resulting in inflated revenue [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - As a result of these practices, Zynex is likely to face adverse consequences, including removal from insurer networks and penalties from the federal government [1]. Group 2: Class Action Details - The class period for the lawsuit is from March 13, 2023, to March 11, 2025 [1]. - Shareholders are encouraged to register for the class action by May 19, 2025, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the case [2]. Group 3: The Gross Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered from deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of a company's stock [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Zynex securities lawsuit is from March 13, 2023, to March 11, 2025, and the lead plaintiff deadline is May 19, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, which inflated its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, leading to potential adverse consequences [4] - The lawsuit argues that the positive statements made by Zynex regarding its business and operations were materially misleading [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Zynex securities is from March 13, 2023, to March 11, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 19, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, inflating its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, leading to potential adverse consequences [4] - The lawsuit asserts that the positive statements made by Zynex regarding its business and operations were materially misleading [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=143342&from=4 CLASS PERIOD: March 13, 2023 to March 11, 2 ...

Core Viewpoint - Zynex, Inc. is facing significant financial, regulatory, and legal challenges, including a class action lawsuit and a downgrade in stock outlook by RBC Capital Markets, which has reduced its price target to $5 per share from an initial $11, reflecting a 55% decrease in valuation outlook [1][2][3]. Financial Performance - The company reported a disappointing fourth-quarter 2024 earnings report with a year-over-year revenue decline of approximately 2%, totaling $46.0 million, and a net loss of $0.02 per share compared to a profit of $0.04 per share in the same period the previous year [3][5]. - RBC Capital Markets has downgraded Zynex's rating to "Sector Perform" from "Outperform," citing a lack of clarity regarding the company's operational and commercial prospects following the recent financial disclosures [4]. Legal and Regulatory Issues - Zynex is facing a securities class action lawsuit alleging that the company engaged in an "oversupplying" scheme, which purportedly inflated revenue figures and drew scrutiny from insurers, including Tricare [7][8]. - The lawsuit claims that Zynex failed to disclose the potential adverse consequences of its practices, which could lead to network exclusions and government penalties [7]. - The temporary suspension of payments from Tricare, Zynex's largest customer, is a significant factor affecting the company's financial stability, as the insurer reviews past claims [5][6]. Investor Sentiment - The recent developments, including the lowered outlook and specifics of the class action, have raised serious concerns among investors regarding Zynex's disclosures and overall accountability [11].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for alleged misconduct during the class period from March 13, 2023, to March 11, 2025, following reports of oversupplying medical devices and a significant revenue shortfall due to payment delays from insurers [1][4]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Legal Developments - A class action lawsuit has been initiated on behalf of investors who purchased Zynex securities during the specified class period, with a deadline of May 19, 2025, for potential lead plaintiff applications [1][2]. - The lawsuit follows a report by medical journal STAT, which accused Zynex of an "oversupplying scheme" that led to insurers removing the company from their networks [3]. Financial Performance - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 and the full year of 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [4]. - Following the financial report, Zynex's stock price plummeted by $3.59 per share, or 51%, closing at $3.41 per share on March 12, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, to close at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. alleging securities fraud that affected investors between March 13, 2023, and March 11, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The complaint suggests that Zynex may face adverse consequences such as removal from insurer networks and federal penalties due to these practices [2]. - Defendants' positive statements regarding Zynex's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the specified timeframe have until May 19, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...